Mersana Says FDA Lifts Clinical Hold on Gastric-Cancer Treatment Phase I Trial
31 Octubre 2023 - 7:07AM
Noticias Dow Jones
By Rob Curran
Biotech company Mersana Therapeutics said the Food and Drug
Administration lifted a clinical hold on a Phase 1 trial of one of
its cancer-treatment candidates.
In March, Mersana said the Food and Drug Administration had
issued a clinical hold on the early-stage trial of the
gastric-cancer drug candidate because of serious adverse
effects.
Based on a review of data, Mersana lowered the starting dose in
the Phase 1 dose escalation design, the company said.
In July, Mersana Therapeutics launched a broad restructuring
following the failure of its lead product candidate in a late-stage
study.
Write to Rob Curran at rob.curran@wsj.com
(END) Dow Jones Newswires
October 31, 2023 08:52 ET (12:52 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Mersana Therapeutics (NASDAQ:MRSN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Mersana Therapeutics (NASDAQ:MRSN)
Gráfica de Acción Histórica
De May 2023 a May 2024
